Fri. 8 Mar 2024, 2:20am ET
Benzinga
News
- The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants
- The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University
- The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world